Get the Stockscreener App
4.87
1.25%
0.06
After Hours:
4.87
Abeona Therapeutics Inc stock is traded at $4.87, with a volume of 623.54K.
It is up +1.25% in the last 24 hours and up +0.41% over the past month.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
See More
Previous Close:
$4.81
Open:
$4.96
24h Volume:
623.54K
Relative Volume:
0.51
Market Cap:
$277.83M
Revenue:
$5.82M
Net Income/Loss:
$71.18M
P/E Ratio:
4.8837
EPS:
0.9972
Net Cash Flow:
$-84.30M
1W Performance:
+6.33%
1M Performance:
+0.41%
6M Performance:
-12.09%
1Y Performance:
+12.73%
1-Day Range:
$4.825
$4.98
1-Week Range:
$4.50
$4.98
52-Week Range:
$3.9328
$7.5401
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Name
Abeona Therapeutics Inc
Sector
Industry
Phone
646-813-4701
Address
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Compare ABEO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
4.87 | 274.41M | 5.82M | 71.18M | -84.30M | 0.9972 |
VRTX
Vertex Pharmaceuticals Inc
|
443.92 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
775.53 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
785.07 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
327.25 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.19 | 33.72B | 5.36B | 287.73M | 924.18M | 2.5229 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Mar-05-25 | Initiated | Oppenheimer | Outperform |
| Jul-03-24 | Initiated | H.C. Wainwright | Buy |
| May-30-24 | Initiated | Stifel | Buy |
| Nov-11-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Feb-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-10-19 | Resumed | Cantor Fitzgerald | Neutral |
| Aug-15-19 | Downgrade | Maxim Group | Buy → Hold |
| Aug-12-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-26-19 | Downgrade | Mizuho | Buy → Neutral |
| Jun-27-19 | Initiated | Mizuho | Buy |
| Oct-12-18 | Initiated | Mizuho | Buy |
| Jun-05-18 | Initiated | Seaport Global Securities | Buy |
| Nov-08-17 | Initiated | SunTrust | Buy |
| Oct-16-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-11-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Oct-10-17 | Initiated | Citigroup | Buy |
| Oct-05-17 | Reiterated | Maxim Group | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Jul-18-17 | Reiterated | Maxim Group | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Jan-06-17 | Initiated | Jefferies | Buy |
| Sep-29-16 | Reiterated | Maxim Group | Buy |
View All
Abeona Therapeutics Inc Stock (ABEO) Latest News
Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors - Sahm
Abeona Therapeutics names Keith Goldan to board of directors By Investing.com - Investing.com India
Abeona Therapeutics Announces Appointment of Keith A. Goldan to its Board of Directors - Bitget
Abeona Therapeutics Appoints Keith A. Goldan to Board - National Today
Abeona Therapeutics Appoints Keith A. Goldan to Board of Directors and Audit Committee to Support Commercial Growth - Minichart
Abeona Therapeutics Adds Keith Goldan to Board, Audit Chair - TipRanks
[Form 4] ABEONA THERAPEUTICS INC. Insider Trading Activity - Stock Titan
Abeona Therapeutics (ABEO) director Form 3 lists no stock trades - Stock Titan
Keith A. Goldan appointed to Abeona Therapeutics' board, named Audit Committee Chair - TradingView
Form 8-KCurrent report - ADVFN
Biotech Abeona taps veteran CFO Keith Goldan to oversee audits - Stock Titan
Abeona Therapeutics (ABEO) — 3.01M shares disclosed by Funicular/Cable Car (5.3%) - Stock Titan
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ChartMill
Panic Selling: Should I set a stop loss on Abeona Therapeutics Inc2026 Chart Watch & Detailed Earnings Play Alerts - baoquankhu1.vn
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York - Sahm
ABEO PE Ratio & Valuation, Is ABEO Overvalued - Intellectia AI
ABEO Should I Buy - Intellectia AI
Abeona Therapeutics Inc. (NASDAQ:ABEO) Q4 2025 earnings call transcript - MSN
ABEO Technical Analysis & Stock Price Forecast - Intellectia AI
Insider Sell: Vishwas Seshadri Sells 29,985 Shares of Abeona The - GuruFocus
Abeona Therapeutics CEO Seshadri Vishwas sells $131k in stock By Investing.com - Investing.com South Africa
Abeona Therapeutics CEO Seshadri Vishwas sells $131k in stock - Investing.com
Abeona (ABEO) CEO sells 29,985 shares under Rule 10b5-1 plan - stocktitan.net
ABEO (NASDAQ: ABEO) Form 144: 29,985 restricted shares proposed sale - Stock Titan
Daniel Kaufman files Schedule 13G — Abeona (NASDAQ: ABEO) 5.16% stake - Stock Titan
Vanguard disaggregates holdings; ABEO ownership shown as 0 (ABEO) - stocktitan.net
Meme Stocks: Does Abeona Therapeutics Inc have strong EBITDA margins2026 Earnings Surprises & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
HC Wainwright Issues Pessimistic Outlook for ABEO Earnings - MarketBeat
Oppenheimer Maintains Outperform on Abeona Therapeutics (ABEO) PT $22 March 2026 - Meyka
Abeona Therapeutics Adopts Third Amended and Restated Bylaws Effective March 16, 2026 - Minichart
Form 8K Abeona Therapeutics Inc For: 20 March By Investing.com - Investing.com Australia
Form 8K Abeona Therapeutics Inc For: 20 March - Investing.com
Abeona Therapeutics Tightens Shareholder Meeting and Governance Rules - TipRanks
Abeona (NASDAQ: ABEO) tightens bylaws on meetings and director nominations - Stock Titan
Abeona Therapeutics Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Abeona Therapeutics Earnings Notes - Trefis
Abeona Therapeutics: Maintaining 'Buy' On ZEVASKYN Launch Potential For RDEB - Seeking Alpha
HC Wainwright & Co. Reiterates Buy Rating for Abeona Therapeutics (ABEO) | ABEO Stock News - GuruFocus
Abeona Therapeutics (NASDAQ:ABEO) Earns Buy Rating from HC Wainwright - MarketBeat
Abeona Therapeutics (ABEO) Receives a Buy from Oppenheimer - The Globe and Mail
Abeona Therapeutics Inc. (NASDAQ:ABEO) Q4 2025 Earnings Call Transcript - Insider Monkey
Abeona Therapeutics Balances Big Windfall With Slow Ramp - The Globe and Mail
Abeona Therapeutics: Early Zevaskyn Revenue Marks A Key Inflection Point (NASDAQ:ABEO) - Seeking Alpha
Abeona Therapeutics (ABEO) One Off US$152.4m Gain Tests Bullish Profitability Narrative - simplywall.st
Abeona targets activation of 7 QTCs for ZEVASKYN by end of 2026 as patient demand doubles - MSN
Stifel cuts Abeona Therapeutics stock price target on sales timing By Investing.com - Investing.com India
Oppenheimer reiterates Abeona Therapeutics stock rating at Outperform By Investing.com - Investing.com Canada
Stifel cuts Abeona Therapeutics stock price target on sales timing - Investing.com
Abeona Therapeutics Inc (ABEO) Q4 2025 Earnings Call Highlights: - GuruFocus
Abeona Therapeutics Reports 2025 Financial Results, ZEVASKYN Launch Momentum, and $191.4M Cash Position - Minichart
Abeona Therapeutics Inc Stock (ABEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.51%
1.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):